This is a StreetInsider.com Premium Only Page

C4 Therapeutics Inc. (CCCC) – StreetInsider.com Reports

Mar 4, 2024 12:37 PM C4 Therapeutics (CCCC) PT Raised to $14 at Jefferies

Mar 4, 2024 07:01 AM C4 Therapeutics (CCCC) Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 27, 2024 12:05 PM C4 Therapeutics (CCCC) PT Lowered to $18 at UBS, 'well funded, multiple catalysts - one to watch in '24'

Feb 26, 2024 08:27 AM C4 Therapeutics (CCCC) PT Raised to $8 at Morgan Stanley

Feb 23, 2024 07:09 AM C4 Therapeutics (CCCC) PT Raised to $13 at Stifel

Feb 23, 2024 06:43 AM C4 Therapeutics (CCCC) PT Raised to $19 at BMO Capital

Feb 23, 2024 05:45 AM C4 Therapeutics (CCCC) PT Raised to $7 at Wells Fargo

Jan 29, 2024 04:27 AM JPMorgan Upgrades C4 Therapeutics (CCCC) to Neutral

Jan 9, 2024 04:01 PM C4 Therapeutics (CCCC) Announces 2024 Priorities and Extended Cash Runway

Dec 22, 2023 04:28 PM C4 Therapeutics Inc. (CCCC): Commodore Capital LP reports 7.7% passive stake

Dec 12, 2023 07:36 PM Stifel Upgrades C4 Therapeutics (CCCC) to Buy

Dec 12, 2023 04:01 PM C4 Therapeutics (CCCC) Reports Positive Data from CFT7455 Phase 1 Trial

Dec 12, 2023 07:13 AM C4 Therapeutics (CCCC) Climbs 28% Following Pact with Merck (MRK)

Dec 12, 2023 07:00 AM C4 Therapeutics Inc. (CCCC) Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates

Nov 20, 2023 07:01 AM C4 Therapeutics Inc. (CCCC) Appoints Owen Hughes to its Board

Nov 6, 2023 04:30 AM Morgan Stanley Upgrades C4 Therapeutics (CCCC) to Equalweight

Nov 2, 2023 08:39 AM C4 Therapeutics (CCCC) PT Lowered to $2 at Stifel

Nov 2, 2023 06:43 AM C4 Therapeutics (CCCC) PT Lowered to $7 at H.C. Wainwright

Nov 2, 2023 06:41 AM C4 Therapeutics (CCCC) PT Lowered to $16 at BMO Capital

Nov 2, 2023 06:21 AM C4 Therapeutics (CCCC) PT Lowered to $6 at Wells Fargo

Oct 11, 2023 07:01 AM C4 Therapeutics Inc. (CCCC) Announces Upcoming Data Presentations for CFT8634

Oct 9, 2023 06:07 AM C4 Therapeutics (CCCC) PT Lowered to $2 at BofA Securities

Sep 5, 2023 04:01 PM C4 Therapeutics Inc. (CCCC) Announces CFO Change

Aug 11, 2023 08:04 AM C4 Therapeutics (CCCC) PT Lowered to $15 at Jefferies

Aug 9, 2023 08:24 AM C4 Therapeutics (CCCC) PT Lowered to $5 at Stifel

Aug 8, 2023 08:15 AM C4 Therapeutics, Inc. (CCCC) Misses Q2 EPS by 1c

Jul 21, 2023 08:24 AM C4 Therapeutics (CCCC) PT Lowered to $20 at UBS

Jul 5, 2023 07:01 AM C4 Therapeutics (CCCC) Announces FDA Clearance of Investigational NDA for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for NSCLC

Jun 20, 2023 07:03 AM C4 Therapeutics Inc. (CCCC) Appoints Leonard Reyno as Chief Medical Officer

May 30, 2023 07:10 AM C4 Therapeutics (CCCC), Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGF

May 30, 2023 06:26 AM C4 Therapeutics (CCCC) PT Lowered to $10 at Evercore ISI, Transfers Coverage

May 12, 2023 07:59 AM C4 Therapeutics (CCCC) PT Lowered to $3 at Morgan Stanley

May 8, 2023 06:35 AM C4 Therapeutics (CCCC) PT Lowered to $25 at H.C. Wainwright

May 5, 2023 08:25 AM C4 Therapeutics (CCCC) PT Lowered to $6 at Stifel

Mar 28, 2023 09:36 AM C4 Therapeutics (CCCC) PT Lowered to $5 at BofA Securities

Feb 27, 2023 07:54 AM C4 Therapeutics (CCCC) PT Lowered to $5 at Morgan Stanley

Feb 24, 2023 01:24 PM Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'

Feb 24, 2023 08:41 AM C4 Therapeutics (CCCC) PT Lowered to $8 at Stifel

Feb 24, 2023 07:18 AM C4 Therapeutics (CCCC) PT Lowered to $22 at UBS

Feb 24, 2023 02:19 AM JPMorgan Downgrades C4 Therapeutics (CCCC) to Underweight

Feb 23, 2023 07:51 AM C4 Therapeutics, Inc. (CCCC) Misses Q4 EPS by 188c

Jan 3, 2023 07:23 AM C4 Therapeutics (CCCC) PT Lowered to $9 at Wells Fargo

Nov 8, 2022 07:04 AM C4 Therapeutics (CCCC) PT Lowered to $11 at Wells Fargo

Nov 4, 2022 08:53 AM C4 Therapeutics (CCCC) PT Lowered to $24 at UBS

Nov 4, 2022 08:31 AM C4 Therapeutics (CCCC) PT Lowered to $12 at Stifel

Nov 4, 2022 06:11 AM UPDATE: JPMorgan Downgrades C4 Therapeutics (CCCC) to Neutral

Oct 11, 2022 06:14 AM Morgan Stanley Starts C4 Therapeutics (CCCC) at Underweight

Sep 29, 2022 07:01 AM C4 Therapeutics Inc. (CCCC) Receives Study May Proceed Letter from FDA to Initiate Phase 1/2 Clinical Trial of CFT1946

Aug 5, 2022 06:29 AM C4 Therapeutics (CCCC) PT Raised to $12 at Credit Suisse

Aug 4, 2022 03:50 PM C4 Therapeutics (CCCC) PT Lowered to $13 at Stifel